



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Director’s Shareholding**

**London: Monday, 19 January 2009:** Chi-Med was informed on 16 January 2009 that Mr Michael Howell, Independent Non-executive Director of Chi-Med, purchased 100,000 ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) at a price of 42.5p each on 15 January 2009.

Following this purchase, Mr Howell is beneficially interested in 143,000 Shares, representing approximately 0.3% of the current issued share capital of Chi-Med.

**Ends**

**Enquiries**

**Chi-Med** Telephone: +852 2121 8200  
Christian Hogg, CEO

**Citigate Dewe Rogerson** Telephone: +44 (0) 20 7638 9571  
Anthony Carlisle +44 (0) 7973 611 888  
David Dible +44 (0) 7967 566 919

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.